ArticleBMC health services research2015

Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.

M Charokopou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.